Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Evaluation of Gentamicin-Entrapped Solid Lipid Microparticles Formulated with a Biodegradable Homolipid from Capra hircus

FC Kenechukwu1 , CE Umeyor2, MA Momoh1, JDN Ogbonna1, SA Chime3, PO Nnamani1, AA Attama1

1Department of Pharmaceutics, University of Nigeria, Nsukka 410001; 2Department of Pharmaceutics and Pharmaceutical Technology, Nnamdi Azikiwe University, Awka; 3Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka 410001, Nigeria.

For correspondence:-   Kenechukwu   Email: chimafrankduff@yahoo.com   Tel:+2348038362638

Received: 5 October 2013        Accepted: 15 June 2014        Published: 18 August 2014

Citation: Kenechukwu F, Umeyor C, Momoh M, Ogbonna J, Chime S, Nnamani P, et al. Evaluation of Gentamicin-Entrapped Solid Lipid Microparticles Formulated with a Biodegradable Homolipid from Capra hircus. Trop J Pharm Res 2014; 13(8):1199-1205 doi: 10.4314/tjpr.v13i8.2

© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To formulate solidified reverse micellar solutions (SRMS)-based solid lipid microparticles (SLMs) using homolipid from Capra hircus, and evaluate its suitability for the delivery of gentamicin.
Methods: SLMs were formulated by melt-emulsification using SRMS (15 % w/w Phospholipon® 90G in 35 % w/w Capra hircus), PEG 4000 and gentamicin (1.0, 2.0 and 3.0 % w/w), and characterized with respect to size, morphology, encapsulation efficiency (EE) and pH-dependent stability. In vitro release of gentamicin from the SLMs was performed in phosphate buffer (pH 7.4) while bioevaluation was carried out using clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus. 
Results: Stable and discrete SLMs of size range 1.47 ± 0.02 to 3.55 ± 0.09 µm were obtained. The SLMs showed a biphasic pattern of drug release and exhibited time-dependent and capacity-limited bioactivity. Overall, SLMs containing 2 % w/w SRMS, 3 % w/w gentamicin and PEG 4000  entrapped the highest amount of drug, released 99 % of drug and  gave the highest inhibitory zone diameter (IZD) against the organisms within 420 min, while plain gentamicin gave the least.
Conclusion: SRMS-based SLMs prepared with homolipid from Capra hircus offers a suitable delivery system for gentamicin.

Keywords: Solid lipid microparticles, Gentamicin, Capra hircus, Phospholipon® 90 G, Solidified reverse micellar solution

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates